3-乙基-3H-咪唑并[4,5-c]吡啶 | 120759-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 3-乙基-3H-咪唑并[4,5-c]吡啶
• 英文名称: 3-ethyl-3H-imidazo<4,5-c>pyridine
• 英文别名: 3-ethyl-3H-imidazo[4,5-c]pyridine；3-ethylimidazo[4,5-c]pyridine
• CAS: 120759-66-2
• 化学式: C₈H₉N₃
• 分子量: 147.18
• InChiKey: QGAVTCWIKMXDFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-乙基-3H-咪唑并[4,5-c]吡啶 在 sulfur 作用下， 反应 0.67h， 以60%的产率得到3-ethyl-1H-imidazo[4,5-c]pyridine-2-thione
  参考文献：
  名称：

  Thionation of imidazopyridines

  摘要：

  DOI：

  10.1007/bf00475602
• 作为产物：
  描述：

  甲酸戊酯 、 N3-乙基-3,4-吡啶二胺 反应 3.5h， 以90%的产率得到3-乙基-3H-咪唑并[4,5-c]吡啶
  参考文献：
  名称：

  Thionation of imidazopyridines

  摘要：

  DOI：

  10.1007/bf00475602

文献信息

• CO₂ as a C1 Source: B(C₆F₅)₃-Catalyzed Cyclization of <i>o</i>-Phenylene-diamines To Construct Benzimidazoles in the Presence of Hydrosilane
  作者：Zhenbei Zhang、Qiangsheng Sun、Chungu Xia、Wei Sun

  DOI：10.1021/acs.orglett.6b03030

  日期：2016.12.16

  B(C6F5)3-catalyzed synthesis of benzimidazoles via cyclization of o-phenylenediamines with CO2 and PhSiH3. This metal-free catalytic route achieves the desired products in high yield under convenient reaction conditions and is applicable to a broad substrate scope. A plausible mechanism for the reaction involving a frustrated Lewis pair pathway is proposed based on spectroscopic characterization (e.g., 13C NMR) of

  使用CO 2作为碳源催化构建苯并咪唑代表了获得这些有价值的化合物的简便且可持续的方法。在这里，我们描述了B（C 6 F 5）3催化的邻苯二胺与CO 2和PhSiH 3的环化反应，合成苯并咪唑。这种无金属的催化途径可以在方便的反应条件下以高收率获得所需的产物，并适用于广泛的底物范围。基于反应中间体的光谱表征（例如13 C NMR），提出了涉及沮丧的路易斯对途径的反应的合理机制。
• [EN] NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO<br/>[FR] NOUVEAUX COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS CORRESPONDANTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010149684A1

  公开（公告）日：2010-12-29

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R1, R2, R3, n, p, q, and Ar are as defined herein, including stereoisomers, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明公开了具有结构(I)的新化合物，其在患者中治疗各种与代谢相关的病症具有实用性：其中R1、R2、R3、n、p、q和Ar如本文所定义，包括立体异构体、溶剂合物和药学上可接受的盐。还公开了包含本发明化合物的药物组合物，以及关于其在有需要的患者中使用的方法。
• [EN] NOVEL PDE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION<br/>[FR] NOUVEAUX INHIBITEURS DE PHOSPHODIESTÉRASES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：MATRIX LAB LTD

  公开号：WO2009147476A1

  公开（公告）日：2009-12-10

  The present invention relates to novel heterocyclic compounds of general formula (I), which are phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors, pharmaceutical compositions containing them, and processes for their preparation. These novel PDEs are useful in treating allergic and inflammatory diseases (such as asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and central nervous system(CNS) disorders) and for inhibiting the production of Tumor Necrosis Factor(TNF-α).

  本发明涉及一种新型杂环化合物，其一般式为(I)，它们是磷酸二酯酶抑制剂（PDEs），特别是磷酸二酯酶4型抑制剂，包含它们的制药组合物以及它们的制备方法。这些新型PDEs在治疗过敏和炎症性疾病（如哮喘、慢性阻塞性肺病、过敏性鼻炎、过敏性结膜炎、呼吸窘迫综合征、慢性支气管炎、肾炎、类风湿脊柱炎、骨关节炎、特应性皮炎、嗜酸性肉芽肿、银屑病、类风湿败血症、溃疡性结肠炎、多发性硬化症、慢性炎症、克罗恩综合征和中枢神经系统（CNS）疾病）以及抑制肿瘤坏死因子（TNF-α）的产生方面具有用途。
• Fused heterocyclic derivatives and methods of use
  申请人：Albrecht Brian K.

  公开号：US20090124612A1

  公开（公告）日：2009-05-14

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗疾病，如HGF介导的疾病具有有效性。本发明包括新颖的化合物、类似物、前药和其药学上可接受的盐、药物组合物和预防和治疗涉及癌症等疾病和其他疾病或病况的方法。该发明还涉及制备这样的化合物的过程，以及在这样的过程中有用的中间体。
• FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
  申请人：ALBRECHT Brian K.

  公开号：US20120148531A1

  公开（公告）日：2012-06-14

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的化合物对于预防和治疗疾病，如HGF介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐、制药组合物以及用于预防和治疗涉及癌症等疾病和其他疾病或病情的方法。该发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。